Table I.
Clinicopathological characteristics of TACE-treated and non-TACE-treated patients with HCC.
| Clinicopathological characteristics | Non-TACE HCC patients (n=30) | TACE HCC patients (n=27) |
|---|---|---|
| Sex | ||
| Male | 24 | 26 |
| Female | 6 | 1 |
| Age (years), median (range) | 56 (24-81) | 57 (36-70) |
| pTNM stage | ||
| Early (I-II) | 7 | 5 |
| Advanced (III-IV) | 23 | 22 |
| Venous infiltrationa | ||
| Absent | 11 | 13 |
| Present | 19 | 11 |
| Number of tumors | ||
| Single | 19 | 10 |
| Multiple | 11 | 17 |
| Tumor size (cm) | ||
| <5 | 16 | 11 |
| ≥5 | 14 | 16 |
| α fetoprotein level (ng/ml) | ||
| <20 | 13 | 10 |
| ≥20 | 17 | 17 |
| Hepatitis B surface antigen | ||
| Negative | 5 | 5 |
| Positive | 25 | 22 |
a
Data for 3 patients were not available. TACE, transarterial chemoembolization; HCC, hepatocellular carcinoma.